Ibrutinib: An Irreversible Inhibitor of Bruton’s Tyrosine Kinase

Abstract

Ibrutinib is an orally administered small molecule that acts as an irreversible inhibitor of Bruton’s tyrosine kinase (BTK), a pivotal enzyme in the B-cell receptor (BCR) signaling pathway. Initially approved by the FDA in 2013 for mantle cell lymphoma, ibrutinib’s indications have since expanded to include chronic lymphocytic leukemia (CLL), Waldenström’s macroglobulinemia, and marginal zone lymphoma. Structurally, ibrutinib (C₂₅H₂₄N₆O₂; MW: 440.5 g/mol) contains a reactive acrylamide group that enables irreversible covalent binding to BTK. Its four-step synthesis comprises Mitsunobu coupling, Boc deprotection, Suzuki-Miyaura coupling, and a final acylation with acryloyl chloride. Pharmacodynamically, ibrutinib disrupts BCR-mediated proliferation signals critical to B-cell malignancies. Despite rapid oral absorption (Tmax: 1–2 h), its absolute bioavailability is very low (~3%) due to extensive first-pass metabolism by CYP3A4. The drug features a large apparent volume of distribution (~10,000 L) and high plasma protein binding (97%). UHPLC-MS/MS in MRM mode is the reference analytical method for quantifying ibrutinib in biological matrices, offering high sensitivity and specificity. These pharmacological and analytical characteristics establish ibrutinib as a landmark targeted therapy for B-cell malignancies.